Could your own tumor become a vaccine? new trial aims to train the immune system against breast cancer
NCT ID NCT03804944
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a new approach for post-menopausal women with HR+HER2- breast cancer. Participants receive standard hormone therapy plus focal radiation, and some also get the immunotherapy drug pembrolizumab and an immune booster (CDX-301). The goal is to see if this combination can turn the tumor into a personalized vaccine that triggers a stronger immune response. The study will check for safety and measure how well the tumor shrinks or disappears before surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (immunotherapy drug) and CDX-301 (immune booster), combined with focal radiation therapy
What this could lead to
If successful, this approach could turn a patient's own tumor into a vaccine that helps the immune system fight the cancer more effectively, potentially improving outcomes for HR+ breast cancer.
What could go wrong
This is a small, early-phase trial (100 participants) testing safety and initial effectiveness. The combination may cause side effects, and it's unknown if it will work better than standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brooklyn Methodist Hospital - NewYork Presbyterian
RECRUITINGNew York, New York, 11215, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cedars-Sinai Medical Center
WITHDRAWNLos Angeles, California, 90048, United States
-
Houston Methodist Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Icahn School of Medicine at Mt Sinai
WITHDRAWNNew York, New York, 10027, United States
-
New York Presbyterian Hospital - Queens
RECRUITINGNew York, New York, 10065, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UPMC Hillman Cancer Center
WITHDRAWNPittsburgh, Pennsylvania, 15232, United States
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390-9179, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Weill Cornell Medicine New York Presbyterian Hospital
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact